<DOC>
	<DOCNO>NCT00006037</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . IM-862 may stop growth colorectal cancer stop blood flow tumor . It yet know chemotherapy effective without IM-862 treat colorectal cancer . PURPOSE : Randomized phase II trial study effectiveness chemotherapy plus IM-862 treating patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Chemotherapy Plus IM-862 Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy fluorouracil without IM-862 term progression free survival patient previously untreated recurrent metastatic adenocarcinoma colon rectum . II . Determine toxicity IM-862 fluorouracil patient . III . Determine efficacy IM-862 combination irinotecan term progression free survival patient disease progression receive fluorouracil . IV . Obtain preliminary data molecular marker response time progression determine level gene involve adhesion , angiogenesis , apoptosis , drug resistance prior chemotherapy . V. Determine molecular correlate response time progression analysis serum urine marker angiogenesis , vascular endothelial growth factor fibroblast growth factor , patient treat IM-862 combination fluorouracil irinotecan . VI . Compare quality life patient treat regimen . OUTLINE : This randomize , double blind , placebo control , crossover study . Patients randomize one two treatment arm : Arm I : Patients receive fluorouracil IV continuously day 1-21 IM-862 intranasally three time daily day 1-28 . Courses repeat every 4 week absence disease progression . Patients develop disease progression take fluorouracil IM-862 , receive irinotecan IV 90 minute weekly 4 week . Courses repeat every 6 week absence disease progression . Arm II : Patients receive fluorouracil arm I placebo intranasally three time daily day 1-28 . Courses repeat every 4 week absence disease progression . Patients develop disease progression take fluorouracil placebo , receive irinotecan IM-862 arm I day 1-42 . Courses repeat every 6 week absence disease progression . Quality life assess prior study , prior every course study . Patients follow minimum 6 month . PROJECTED ACCRUAL : A total 66 patient ( 33 per arm ) accrue study within 26-27 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Thymogen</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic adenocarcinoma colon rectum Previously untreated OR Recurrent disease free period least 1 year Measurable evaluable disease Tumor must accessible biopsy No brain metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) ( great 3 time ULN liver metastasis present ) AST ALT great 2 time ULN ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 1.25 time ULN Cardiovascular : No myocardial infarction within past year No congestive heart failure Other : No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month study No medical , social , psychological factor would interfere compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Prior adjuvant immunotherapy monoclonal antibody 171A allow No prior IM862 Chemotherapy : At least 1 year since prior chemotherapy patient recurrent metastatic adenocarcinoma colon rectum Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>